Trial reportScientific reports2022
An open label randomized clinical trial of Indomethacin for mild and moderate hospitalised Covid-19 patients.
Trial report in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 41 citations in OpenAlex.
- Comparison of Preprint Postings of Randomized Clinical Trials on COVID-19 and Corresponding Published Journal Articles: A Systematic Review.JAMA network open · 2023Pooled it
- The potential role of indomethacin in COVID-19 management: A systematic review of therapeutic and mechanistic evidence.New microbes and new infections · 2026Review
- Antiviral activity of the non-steroidal anti-inflammatory drug indomethacin against respiratory syncytial virus.Virus research · 2026Article
- Prostaglandin D2 delays CD8+ T-cell responses and respiratory syncytial virus clearance in geriatric cotton rats.Journal of virology · 2025Article
- Indomethacin inhibits human seasonal coronaviruses at late stages of viral replication in lung cells: Impact on virus-induced COX-2 expression.Journal of virus eradication · 2024Article
- Long Neuro-COVID-19: Current Mechanistic Views and Therapeutic Perspectives.Biomolecules · 2024Review
- Combination of Indomethacin with Nanostructured Lipid Carriers for Effective Anticancer Therapy.International journal of nanomedicine · 2024Article
- Does haste make waste? Prevalence and types of errors reported after publication of studies of COVID-19 therapeutics.Systematic reviews · 2023Review
- Ibuprofen, other NSAIDs and COVID-19: a narrative review.Inflammopharmacology · 2023Review
- Combating pan-coronavirus infection by indomethacin through simultaneously inhibiting viral replication and inflammatory response.iScience · 2023Article
- Indole-Based Compounds as Potential Drug Candidates for SARS-CoV-2.Molecules (Basel, Switzerland) · 2023Review
- Renin-Angiotensin System Components and Arachidonic Acid Metabolites as Biomarkers of COVID-19.Biomedicines · 2023Article
- Protein structure-based in-silico approaches to drug discovery: Guide to COVID-19 therapeutics.Molecular aspects of medicine · 2023Review
- Hypothesis: Efficacy of early treatments with some NSAIDs in COVID-19: Might it also depend on their direct and/or indirect zinc chelating ability?British journal of pharmacology · 2023Article
- Sustainable Photoinduced Decarboxylative Chlorination Mediated by Halogen Atom Transfer.Green chemistry : an international journal and green chemistry resource : GC · 2023Article
- Home as the new frontier for the treatment of COVID-19: the case for anti-inflammatory agents.The Lancet. Infectious diseases · 2023Review
- Article
- Small molecules in the treatment of COVID-19.Signal transduction and targeted therapy · 2022Review
- Full-dose NSAIDs at the first sign of respiratory infection?The Lancet. Infectious diseases · 2022Article
- Article
Corrections and comments
- Erratum issued
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Indomethacin, a non-steroidal anti-inflammatory drug (NSAID), has been presented as a broad-spectrum antiviral agent. This randomised clinical trial in a hospital setting evaluated the efficacy and safety of this drug in RT-PCR-positive coronavirus disease 2019 (COVID-19) patients. A total of 210 RT-PCR-positive COVID-19 patients who provided consent were allotted to the control or case arm, based on block randomisation. The control arm received standard of care comprising paracetamol, ivermectin, and other adjuvant therapies. The patients in the case arm received indomethacin instead of paracetamol, with other medications retained. The primary endpoint was the development of hypoxia/desaturation with SpO
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.